The effect of neuroimmune modulation on subjective response to alcohol in the natural environment.

ABSTRACT:

Background

Despite the promising implications for novel immune therapeutics, few clinical trials have tested these therapies to date. An understanding of how immune pharmacotherapies influence complex alcohol use disorder (AUD) profiles, including subjective response to alcohol, is very limited. Initial findings show that ibudilast, a neuroimmune modulator, reduces rates of heavy drinking and measures of alcohol craving.

Methods

This study is a secondary analysis of a 2-week clinical trial of ibudilast that enrolled a nontreatment-seeking sample with AUD. Eligible participants (N = 52) were randomized to receive ibudilast or matched placebo and completed daily diary assessments (DDAs) during the 2-week period. Each morning, participants reported on their mood and craving lev

SUBMITTER: Meredith LR 

PROVIDER: S-EPMC10460619 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature